SOURCE: AspenBio Pharma, Inc.

November 13, 2009 11:45 ET

AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference

CASTLE ROCK, CO--(Marketwire - November 13, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has been invited to present at the Lazard Capital Market 6th Annual Healthcare Conference to be held November 17-18, 2009 at The St. Regis Hotel New York, NY.

Company management is scheduled to present on Tuesday, November 17, 2009 at 9:25 a.m. Eastern time, with one-on-one meetings held throughout the day.

Management will discuss the company's progress, including its recently filed Premarket Notification 510(k) with the U.S. Food and Drug Administration for AppyScore™, the first blood-based test designed to aid in the diagnosing or ruling out human appendicitis.

AspenBio is also advancing a new class of drugs that replace natural reproductive hormones for animals of economic importance. The company has a development and marketing agreement with Novartis Animal Health (NYSE: NVS) for the bovine species.

Leading the presentation will be the company's executive chairman and CEO, Daryl Faulkner, who was previously president, CEO and board member of Digene Corp., a Nasdaq-traded company prior to its acquisition by Qiagen.

For more information, please visit the conference website at http://www.lazardcap.com/conferenceList.aspx?tn=4&ln=3&itm=2123&lid=758 or contact the 2009 Healthcare Conference event team at HealthcareConference@lazardcap.com.

About AspenBio Pharma, Inc.

AspenBio Pharma's mission is to be a leader in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs in both Human and Animal Health. Our Human Health Division is addressing the difficult challenge of diagnosing appendicitis in the hospital emergency department setting. Our Animal Health Division is focused on therapeutic proteins that support reproductive efficiency in animals of economic importance. For more information, go to http://www.aspenbiopharma.com.

About Lazard Capital Markets

Lazard Capital Markets LLC was formed in 2005 concurrent with the recapitalization of Lazard Group LLC and initial public offering of Lazard Ltd. Headquartered in New York's Rockefeller Center, we continue all of the capital markets activities formerly conducted by Lazard Frères & Co. LLC. Lazard Frères & Co. LLC, one of the world's preeminent financial advisory and asset management firms, operates from 39 cities across 21 countries in North America, Europe, Australia, Asia and South America. With origins dating back to 1848, the firm provides advice on mergers and acquisitions, restructuring and capital raising, as well as asset management services, to corporations, partnerships, institutions, governments and individuals.

Contact Information

  • Company Contact:
    Gregory Pusey
    Vice Chairman
    Tel 303-722-4008

    Investor Relations:
    Liolios Group, Inc.
    Email Contact
    Ron Both or Geoffrey Plank
    Tel 949-574-3860